Hansa Biopharma provides updated guidance on its clinical programs
· Idefirix recently granted formal approval by the EU Commission; First treatments expected in select countries in Q4 2020 in the EU · Updating clinical timelines for ongoing and planned imlifidase trials due to continued impact from the COVID-19 pandemic · High-level data read-out from the investigator initiated phase 2 study in anti-GBM expected in Q3, 2020, as previously guidedLund, Sweden September 1, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced updated guidance regarding its ongong and planned